Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 100
- Registration Number
- NCT05744479
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
New Approaches to INOCA
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Pasquale Mone
- Target Recruit Count
- 3000
- Registration Number
- NCT05740345
Metformin Efficacy and Safety in Epileptic Patients
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT05722951
- Locations
- 🇪🇬
Omnia Ashraf Abd El Aziz Ahmed Kotb, Alexandria, Egypt
Cardio-protective Effect of Metformin in Patients Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Future University in Egypt
- Target Recruit Count
- 80
- Registration Number
- NCT05708053
- Locations
- 🇪🇬
Faculty of Pharmacy, Cairo University, Cairo, Egypt
🇪🇬Kasr El Aini Hospital, Cairo, Egypt
🇪🇬Kasr El-Aini Hospital, Cairo, Egypt
Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 34
- Registration Number
- NCT05694221
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 100
- Registration Number
- NCT05680805
- Locations
- 🇧🇩
Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT05680129
- Locations
- 🇨🇳
ZHONGSHAN Hospital, Shanghai, Shanghai, China
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-08-22
- Target Recruit Count
- 60
- Registration Number
- NCT05663749
- Locations
- 🇮🇳
Dept of Psychiatry, Aiims, Bhubaneswar, Bhubaneswar, Odisha, India
Treatment With Metformin in Chinese Children With Alport Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT05655728
Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Khyber Medical University Peshawar
- Target Recruit Count
- 120
- Registration Number
- NCT05653895
- Locations
- 🇵🇰
Bacha Khan Medical Complex Swabi, Swabi, Khyber Pukhtunkhwa, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.